A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, Compared with Placebo in Combination with Docetaxel, in Patients receiving second line treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV)

Trial Profile

A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, Compared with Placebo in Combination with Docetaxel, in Patients receiving second line treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Selumetinib (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms SELECT-2
  • Sponsors AstraZeneca
  • Most Recent Events

    • 03 Oct 2017 Primary endpoint (Progression-Free Survival (PFS)) has not been met as per the results published in the Annals of Oncology
    • 03 Oct 2017 Patients were initially enrolled independently of KRAS mutation status, but the protocol was amended on September 2013 to include only patients with centrally confirmed KRAS wild-type NSCLC
    • 03 Oct 2017 Results (data cut off 27 January 2016) published in the Annals of Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top